GD2/B7-H3 CAR T-cell therapy

drug_type

RELEVANT_DRUG

intervention_type

Gene-modified cellular immunotherapy (CAR T cells)

drug_description

Gene-modified T cells engineered with chimeric antigen receptors targeting GD2 and B7-H3; administered primarily as autologous cells with option for healthy-donor T cells if autologous cells are unsuitable. Designed for MHC-independent tumor recognition, T-cell activation, cytokine release, and cytotoxic killing to reduce antigen escape in GD2/B7-H3–expressing tumors.

nci_thesaurus_definition

NCI thesaurus definition not available.

drug_mesh_term

Chimeric Antigen Receptor T-Cell Therapy

drug_category

CAR T

drug_class

Cellular Therapy

drug_delivery_route

Intravenous

drug_mechanism_of_action

Gene-modified T cells expressing CARs against GD2 and B7-H3 recognize these antigens on tumor cells independent of MHC, triggering T-cell activation, cytokine release, proliferation, and cytotoxic killing; dual-antigen targeting is intended to reduce antigen escape in GD2/B7-H3–expressing tumors.

drug_name

GD2/B7-H3 CAR T-cell therapy

nct_id_drug_ref

NCT06836505